Glaukos Corporation (GKOS) News
Track canonical SquawkNews coverage tagged to GKOS, Glaukos Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 21 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
GKOS - Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
GKOS - Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
NEWS | Sep 23, 2026, 11:05 AM UTC
L
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch
NEWS | Sep 23, 2026, 11:00 AM UTC
L
Epioxa and iDose drive growth as GKOS expands access and pipeline
Epioxa’s commercial launch is progressing as payer access expands and Photrexa sunset continues. iDose and core MIGS businesses are growing, with a pipeline and new screening device supporting future expansion, as manage
EQUITY | Sep 09, 2026, 08:37 PM UTC
L
Epioxa and iDose drive growth as payer access expands and milestones approach
Epioxa’s commercial launch is progressing as payer access expands and Photrexa has been sunset. iDose continues to grow with strong Medicare Advantage uptake, while the pipeline advances with multiple clinical milestones
EQUITY | Sep 09, 2026, 08:01 PM UTC
L
Glaukos (GKOS) to Participate in Wells Fargo Healthcare Conference
Glaukos (GKOS) announces its participation in a Wells Fargo Healthcare Conference, according to TradeXchange Newsdesk.
EQUITY | Aug 19, 2026, 11:03 AM UTC
L
GKOS PT raised from $180 to $215, maintains Buy @ Truist
GKOS PT raised from $180 to $215, maintains Buy @ Truist
EQUITY | Jul 30, 2026, 12:31 PM UTC
L
GKOS Q2 Scraped: adj. EPS $(0.14) vs. est. $(0.22), revenue $185.6Mm vs. est. $151.0Mm, adj. gross margin 85%; FY26 sales guidance raised to
GKOS Q2 Scraped: adj. EPS $(0.14) vs. est. $(0.22), revenue $185.6Mm vs. est. $151.0Mm, adj. gross margin 85%; FY26 sales guidance raised to $680Mm—$700Mm vs. est. $629.98Mm; shares +8.3%
EARNINGS | Jul 29, 2026, 08:38 PM UTC
H
PRCH +20%, CORT +18.3%, BOOM +17.3%, FORM +16.4%, SBUX +10.2%, FTNT +9.4%, BHE +9.3%, LUNG +8.8%, LRCX +7.6%, CMG +7.1%, GKOS +7%, GFL +5.7%
PRCH +20%, CORT +18.3%, BOOM +17.3%, FORM +16.4%, SBUX +10.2%, FTNT +9.4%, BHE +9.3%, LUNG +8.8%, LRCX +7.6%, CMG +7.1%, GKOS +7%, GFL +5.7%, RGR 4.8%, MOD +3.9%, ICLR +3.8%, ST +3.6%, MAX +2.6%, EQIX +2.4% after results
EARNINGS | Jul 29, 2026, 08:27 PM UTC
L
Glaukos Raises FY2026 Sales Guidance from $620.000M-$635.000M to $680.000M-$700.000M vs $629.748M Est
Glaukos (NYSE: GKOS ) raises FY2026 sales outlook from $620.000 million-$635.000 million to $680.000 million-$700.000 million vs $629.748 million estimate.
EARNINGS | Jul 29, 2026, 08:17 PM UTC
L
GKOS - Glaukos Announces Second Quarter 2026 Financial Results
GKOS - Glaukos Announces Second Quarter 2026 Financial Results
EARNINGS | Jul 29, 2026, 08:13 PM UTC
L
GKOS Glaukos RESULTS: Q2, Q2 Net Income $-18.4M, Q2 ADJ Net Income $-8.3M vs. EST $-12.3M, Q2 gross margin 82%, Q2 sales $185.6M vs. EST $15
GKOS Glaukos RESULTS: Q2, Q2 Net Income $-18.4M, Q2 ADJ Net Income $-8.3M vs. EST $-12.3M, Q2 gross margin 82%, Q2 sales $185.6M vs. EST $150.9M, Q2 ADJ gross margin 85%, Glaukos Earnings Notes:, Outlook FY sales $680-70
EARNINGS | Jul 29, 2026, 08:07 PM UTC
L
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutr
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutral rated RXST, Buy rated SGHT) and initiating coverage of Buy rated BLCO, Neutra
EQUITY | Jul 28, 2026, 11:52 AM UTC
L
GKOS Initiated Neutral at UBS
GKOS Initiated Neutral at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
GKOS Reiterate Buy and PT $175 as Epioxa/CXL Deep Dive and Early Epioxa Adopter Survey Checks Strengthen Intermediate-to-Long-Term Bullishne
GKOS Reiterate Buy and PT $175 as Epioxa/CXL Deep Dive and Early Epioxa Adopter Survey Checks Strengthen Intermediate-to-Long-Term Bullishness @ Stifel
EQUITY | Jul 28, 2026, 11:15 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
GKOS d/g Neutral @ UBS
GKOS d/g Neutral @ UBS
EQUITY | Jul 28, 2026, 09:15 AM UTC
L
GKOS Reiterate Buy and raise PT $170 to $175 after iDose Survey Diligence @ Stifel
GKOS Reiterate Buy and raise PT $170 to $175 after iDose Survey Diligence @ Stifel
EQUITY | Jul 17, 2026, 11:06 AM UTC
L
Glaukos Insider Sold Shares Worth $1,550,000, According to a Recent SEC Filing
() -- Alex R. Thurman, Senior Vice President and Chief Financial Officer, on July 09, 2026, sold 10,000 shares in Glaukos (GKOS) for $1,550,000. Following the Form 4 filing with the SEC, Thurman has control over a total
GEOPOLITICS | Jul 14, 2026, 08:10 AM UTC
L
Glaukos Insider Sold Shares Worth $1,500,000, According to a Recent SEC Filing
() -- Alex R. Thurman, Senior Vice President and Chief Financial Officer, on July 06, 2026, sold 10,000 shares in Glaukos (GKOS) for $1,500,000. Following the Form 4 filing with the SEC, Thurman has control over a total
GEOPOLITICS | Jul 09, 2026, 07:06 AM UTC
L
Piper Sandler Reiterates Overweight on Glaukos, Maintains $165 Price Target
Piper Sandler analyst Adam Maeder reiterates Glaukos (NYSE: GKOS ) with a Overweight and maintains $165 price target.
EQUITY | Jul 01, 2026, 01:29 PM UTC
L
GKOS Completes Enrollment
Glaukos completes patient enrollment in Phase 2 study of GLK-321 for Demodex Blepharitis
EQUITY | Jun 25, 2026, 11:11 AM UTC